An FDA-approved treatment for adults with Major Depressive Disorder or Treatment-Resistant Depression, Spravato is an esketamine nasal spray administered in our office. It is used in conjunction with an oral antidepressant in those who have not achieved satisfactory relief of depression symptoms using typical treatment approaches.
What to expect: Depending on the dose your provider believes is appropriate, you will receive two or three nasal inhalers during your visit.
Because esketamine is a version of ketamine, this treatment is only available under supervision in our office. Each treatment session takes approximately two hours and you will not be released until a physician has cleared you for release. Because Spravato can have a sedating effect, you will be restricted from driving following treatment and will need a mode of transportation which does not require you to drive in any manner. You cannot be cleared for release without it.